Trial Profile
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Carcinoid tumour; Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 04 Nov 2019 Status changed from active, no longer recruiting to completed.
- 24 Apr 2019 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 24 Apr 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Mar 2020.